US 12,371,510 B2
Process for concentration of antibodies and therapeutic products thereof
Charles M. Winter, Belmont, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US); and Novartis AG, Basel (CH)
Filed by Genentech, Inc., South San Francisco, CA (US); and Novartis AG, Basel (CH)
Filed on Sep. 10, 2020, as Appl. No. 17/017,465.
Application 17/017,465 is a continuation of application No. 16/752,366, filed on Jan. 24, 2020, abandoned.
Application 16/752,366 is a continuation of application No. 16/447,800, filed on Jun. 20, 2019, abandoned.
Application 16/447,800 is a continuation of application No. 14/257,907, filed on Apr. 21, 2014, granted, now 10,370,456, issued on Aug. 6, 2019.
Application 14/257,907 is a continuation of application No. 11/220,362, filed on Sep. 6, 2005, abandoned.
Claims priority of provisional application 60/609,092, filed on Sep. 9, 2004.
Prior Publication US 2021/0095050 A1, Apr. 1, 2021
Int. Cl. A61K 39/395 (2006.01); B01D 61/14 (2006.01); B01D 61/16 (2006.01); C07K 1/34 (2006.01); C07K 16/06 (2006.01); C07K 16/42 (2006.01)
CPC C07K 16/4291 (2013.01) [A61K 39/39591 (2013.01); B01D 61/146 (2022.08); B01D 61/16 (2013.01); C07K 1/34 (2013.01); C07K 16/065 (2013.01); B01D 2311/04 (2013.01); B01D 2311/16 (2013.01); C07K 2317/21 (2013.01)] 8 Claims
 
1. An ultrafiltration retentate diluted and conditioned to a final formulation comprising about 150 g/L (mg/ml) anti-IgE rhuMab E25 antibody, 0.02 M histidine, 0.2 M arginine-HCl, 0.04% polysorbate 20, pH 6, wherein the anti-IgE rhuMab E25 antibody is as described in U.S. Pat. No. 6,172,213, and wherein the ultrafiltration retentate is substantially free of soluble aggregates of the antibody.